{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:18Z","timestamp":1793018118968,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01910-y","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:33:28Z","timestamp":1790926408000},"page":"5635-5652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0610-5401","authenticated-orcid":false,"given":"Brittney","family":"Wass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-7347","authenticated-orcid":false,"given":"Aidan M.","family":"Fenix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5035-4532","authenticated-orcid":false,"given":"Nina","family":"Zolotarjova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-2044","authenticated-orcid":false,"given":"Guofeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-6047","authenticated-orcid":false,"given":"Leandro L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryssa","family":"Kanellopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8868-2146","authenticated-orcid":false,"given":"Ricardo","family":"Macarr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"12","key":"1910_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","volume":"23","author":"L Castelo-Soccio","year":"2023","unstructured":"Castelo-Soccio L, Kim H, Gadina M, Schwartzberg PL, Laurence A, O\u2019Shea JJ. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023;23(12):787\u2013806.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1910_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649\u201365.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1910_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"1910_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"key":"1910_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"issue":"11","key":"1910_CR6","doi-asserted-by":"publisher","first-page":"12830","DOI":"10.1021\/acs.jmedchem.5c03753","volume":"69","author":"J Zhuo","year":"2026","unstructured":"Zhuo J, Li Y-L, Qian D-Q, et al. Discovery of the orally bioavailable isoform selective Janus kinase 1 (JAK1) compound povorcitinib (INCB054707) for the treatment of inflammatory and autoimmune diseases. J Med Chem. 2026;69(11):12830\u201352.","journal-title":"J Med Chem"},{"key":"1910_CR7","doi-asserted-by":"crossref","unstructured":"Szeto K, Gong X, Xun Z, et al. Skin and plasma pharmacokinetics of povorcitinib following once-daily oral administration in healthy participants: an open-label phase 1 study. JID Innov [in press]. 2026.","DOI":"10.1016\/j.xjidi.2026.100530"},{"issue":"3","key":"1910_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby JS, Okun MM, Alavi A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90(3):521\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1910_CR9","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","volume":"93","author":"AG Pandya","year":"2025","unstructured":"Pandya AG, Ezzedine K, Passeron T, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2025;93(4):946\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"1910_CR10","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1038\/s41591-026-04534-z","volume":"32","author":"ML Porter","year":"2026","unstructured":"Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat Med. 2026;32:3071\u20133081.","journal-title":"Nat Med"},{"issue":"2","key":"1910_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2026.100206","volume":"3","author":"H Celik","year":"2026","unstructured":"Celik H, Wass B, Zolotarjova N, et al. Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. Blood Neoplasia. 2026;3(2):100206.","journal-title":"Blood Neoplasia"},{"issue":"11","key":"1910_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1039\u201345.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"1910_CR13","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"key":"1910_CR14","unstructured":"RINVOQ\u00ae (upadacitinib). Full prescribing information, AbbVie Inc., North Chicago, IL; 2026."},{"key":"1910_CR15","unstructured":"CIBINQO\u00ae (abrocitinib). Full prescribing information, Pfizer Inc, New York, NY; 2026."},{"key":"1910_CR16","unstructured":"OLUMIANT\u00ae (baricitinib). Full prescribing information, Lilly USA, LLC, Indianapolis, IN; 2026."},{"key":"1910_CR17","unstructured":"XELJANZ\u00ae (tofacitinib). Full prescribing information, Pfizer Labs, New York, NY; 2026."},{"issue":"11","key":"1910_CR18","volume":"10","author":"JV Greiner","year":"2021","unstructured":"Greiner JV, Glonek T. Intracellular ATP concentration and implication for cellular evolution. Biology (Basel). 2021;10(11):1166.","journal-title":"Biology (Basel)"},{"issue":"2","key":"1910_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","volume":"23","author":"M Shehab","year":"2025","unstructured":"Shehab M, Alrashed F, Alsayegh A, et al. Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2025;23(2):250\u201362.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"1910_CR20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon R, Mongin D, Guemara R, et al. Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries. Arthritis Rheumatol. 2025;77(9):1194\u2013204.","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"1910_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26164898","volume":"26","author":"A Roth","year":"2021","unstructured":"Roth A, Gihring A, G\u00f6ser F, Peifer C, Knippschild U, Bischof J. Assessing the inhibitory potential of kinase inhibitors in vitro: major pitfalls and suggestions for improving comparability of data using CK1 inhibitors as an example. Molecules. 2021;26(16):4898.","journal-title":"Molecules"},{"key":"1910_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:41.","journal-title":"J Inflamm"},{"issue":"5646","key":"1910_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875\u20138.","journal-title":"Science"},{"issue":"6","key":"1910_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","volume":"7","author":"ME Dowty","year":"2019","unstructured":"Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537.","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"1910_CR25","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307.","journal-title":"J Immunol"},{"issue":"3","key":"1910_CR26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","volume":"61","author":"ML Vazquez","year":"2018","unstructured":"Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N-cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutylpropane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61(3):1130\u201352.","journal-title":"J Med Chem"},{"issue":"8","key":"1910_CR27","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/dmd.122.000829","volume":"50","author":"JN Bauman","year":"2022","unstructured":"Bauman JN, Doran AC, King-Ahmad A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos. 2022;50(8):1106\u201318.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1910_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors. Dermatol Ther. 2021;11(5):1763\u201376.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1910_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052977","volume":"25","author":"C Liongue","year":"2024","unstructured":"Liongue C, Ratnayake T, Basheer F, Ward AC. Janus kinase 3 (JAK3): a critical conserved node in immunity disrupted in immune cell cancer and immunodeficiency. Int J Mol Sci. 2024;25(5):2977.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1910_CR30","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1007\/s43440-025-00789-4","volume":"77","author":"P Rzeczycki","year":"2025","unstructured":"Rzeczycki P, Plust M, Plewa P, D\u0105browska-\u017bamojcin E, Pawlik A. Tyrosine kinase 2 inhibitors in the therapy of inflammatory and autoimmune diseases. Pharmacol Rep. 2025;77(6):1600\u201311.","journal-title":"Pharmacol Rep"},{"key":"1910_CR31","unstructured":"Gong X, Chen X, Xun Z, et al. A phase 1 multiple ascending dose study of INCB054707, a JAK1 inhibitor, in healthy participants. American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 16\u201318 March 2022; virtual."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01910-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:05:51Z","timestamp":1793016351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01910-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01910-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Brittney Wass, Aidan M. Fenix, Nina Zolotarjova, Alex Margulis, Guofeng Zhang, Dominic Sales, Maryanne Covington, Leandro L. Santos, Chryssa Kanellopoulou, Ricardo Macarr\u00f3n report employment by and stock ownership in Incyte Corporation at the time of the study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the preclinical study design without animal models, no institutional review board or ethics committee approval was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}